CHIP 2Alternative Names: Antianaemic oral - Chiasma; CH 2; Chiasma Investigational Product 2; CHIP-2
Latest Information Update: 14 Oct 2015
At a glance
- Originator Chiasma
- Class Antianaemics; Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Anaemia
Most Recent Events
- 14 Oct 2015 Phase-I development is ongoing in Israel
- 01 Oct 2012 Phase-I clinical trials in Anaemia (in patients with chronic kidney disease) in Israel (PO)